Vektor Medical, a prominent figure in the field of arrhythmia care and the developer behind vMap®, an innovative technology that precisely maps arrhythmias using a patient's 12-lead ECG data, proudly announces the recent approval of a novel Category III CPT code by the American Medical Association (AMA) CPT Editorial Panel. This new code is intended to facilitate the utilization of vMap's noninvasive arrhythmia analysis.

vMap, a system for arrhythmia analysis that leverages AI and has received clearance from the FDA, has demonstrated its potential to markedly enhance the outcomes of cardiac ablation procedures, streamline procedural efficiency, and optimize clinical workflows. This forward-thinking solution, which relies on AI-derived arrhythmia analysis, offers valuable insights to assist in making treatment decisions, improve patient triage, and streamline the planning and execution of catheter ablation procedures. Vektor Medical extends its appreciation to the American College of Cardiology and the Heart Rhythm Society for their collaboration and support throughout this process, as their expertise has been instrumental in gaining recognition for this procedure.

Arrhythmias have become an escalating healthcare concern in both the United States and globally. Despite the well-documented efficacy of cardiac ablation in treating cardiac arrhythmias, its adoption rate remains disproportionately low. Clinical studies have underscored vMap's ability to reduce risks, cut costs, and shorten procedure times. Furthermore, it enhances the success rates of ablation therapy and broadens the spectrum of patients who can benefit from ablation procedures. vMap is poised to pave the way for a more effective, accessible, and patient-centric approach to addressing this pressing global health issue.

Source: businesswire.com